Newsroom

Articles
SMS AFYA-YETU

Interview with Natalie Roberts : COVID-19 Alert and SMS Afia Yetu projects

Natalie Roberts is the director of studies at Crash and program manager at the MSF Foundation. During the first wave of the COVID-19 pandemic, she was involved in the implementation of two digital health applications.

Here she discusses the field of digital health and the challenge that COVID represented in the research on these issues. In this interview, we discover the needs behind the "Alerte-Niger" and "SMS Afia Yetu" projects, the stages of their development, but also the obstacles encountered by the MSF teams (the health context, relations with partners, preconceived ideas about the population).

Read more

Headline

A day at Blantyre cervical cancer referral hospital
Articles
Développement de l'offre de rééducation

Rehabilitation after cervical cancer treatment in Malawi: how can access for patients be improved?

In Malawi, many women treated for cervical cancer travel long distances to access rehabilitation care, even though it is essential for their recovery. In Blantyre, as part of MSF’s cervical cancer prevention and treatment programme, the MSF Foundation has been developing and supporting a specialised rehabilitation service for women for the past two years. Today, it is working to decentralise this care to make it more accessible. 

Cervical cancer remains a major public health issue in Malawi. The country has one of the highest prevalence rates in the world: nearly 40% of cancers diagnosed in women are cervical cancer, and the disease causes around 3,000 deaths every year. 

Read more

MSF Foundation in Video

News

Publications

  • Publications
    Étude Fièvre Jaune

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
  • Publications
    Étude Fièvre Jaune

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more

Press Review

No news for now.